Administration of USP7 inhibitor p22077 alleviates Angiotensin II (Ang II)-induced atrial fibrillation in Mice
Hypertension Research · 2024
DOI: 10.1038/s41440-024-01581-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension Research, 2024. Verfasst von Yu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Angiotensin II, Ubiquitin-Specific Peptidase 7. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Atrial fibrillation (AF), the most common cardiac arrhythmia, is an important contributor to mortality and morbidity. Ubquitin-specific protease 7 (USP7), one of the most abundant ubiquitin-specific proteases (USP), participated in many cellular events, such as cell proliferation, apoptosis, and tumourigenesis. However, its role in AF remains unknown. Here, the mice were treated with Ang II infusion to induce the AF model. Echocardiography was used to measure the atrial diameter. Electrical stimulation was programmed to measure the induction and duration of AF. The changes in atrial remodeling were measured using routine histologic analysis. Here, a significant increase in USP7 expression was observed in Ang II-stimulated atrial cardiomyocytes and atrial tissues, as well as in atrial tissues from patients with AF. The administration of p22077, the inhibitor of USP7, attenuated Ang II-induced inducibility and duration of AF, atrial dilatation, connexin dysfunction, atrial fibrosis, atrial inflammation, and atrial oxidase stress, and then inhibited the progression of AF. Mechanistically, the administration of p22077 alleviated Ang II-induced activation of TGF-β/Smad2, NF-κB/NLRP3, NADPH oxidases (NOX2 and NOX4) signals, the up-regulation of CX43, ox-CaMKII, CaMKII, Kir2.1, and down-regulation of SERCA2a. Together, this study, for the first time, suggests that USP7 is a critical driver of AF and revealing USP7 may present a new target for atrial fibrillation therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China.
- Department of pharmacology, College of Basic Medical Sciences, Binzhou Medical University, Yantai, 264003, China.
- Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China. yangxl_1012@yeah.net.
- Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China. yangxl_1012@yeah.net.
- Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China. diana_521@163.com.
Zitieren
APA
Wang, Y., Gu, Y. H., Ren, K. W., Xie, X., Wang, S. H., Zhu, X. X., Wang, L., Yang, X. L., & Bi, H. L. (2024). Administration of USP7 inhibitor p22077 alleviates Angiotensin II (Ang II)-induced atrial fibrillation in Mice. Hypertension Research. https://doi.org/10.1038/s41440-024-01581-2
Vancouver
Wang Y, Gu YH, Ren KW, Xie X, Wang SH, Zhu XX, et al. Administration of USP7 inhibitor p22077 alleviates Angiotensin II (Ang II)-induced atrial fibrillation in Mice. Hypertension Research. 2024. doi:10.1038/s41440-024-01581-2
BibTeX
@article{Wang2024,
author = {Wang, Yu and Gu, Yu-Hui and Ren, Kai-Wen and Xie, Xin and Wang, Shi-Hao and Zhu, Xiao-Xue and Wang, Lei and Yang, Xiao-Lei and Bi, Hai-Lian},
title = {Administration of USP7 inhibitor p22077 alleviates Angiotensin II (Ang II)-induced atrial fibrillation in Mice},
journal = {Hypertension Research},
year = {2024},
doi = {10.1038/s41440-024-01581-2}
}
EUVIMED